Valuation: Sutro Biopharma, Inc.

Market Cap 147M 132M 122M 111M 207M 13.97B 209M 1.46B 580M 7.32B 552M 540M 23.22B P/E 2026 *
-1.08x
P/E 2027 * -1.34x
Enterprise Value 147M 132M 122M 111M 207M 13.97B 209M 1.46B 580M 7.32B 552M 540M 23.22B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 4.65x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-0.17%
1 week-23.14%
Current month-44.94%
1 month-44.49%
3 months-63.06%
6 months-73.59%
Current year-23.34%
1 week 8.11
Extreme 8.11
10.93
1 month 8.11
Extreme 8.11
16.66
Current year 8.11
Extreme 8.11
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 13/03/2025
Director of Finance/CFO 53 02/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 70 01/08/2009
Director/Board Member 67 01/02/2017
Director/Board Member 51 25/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
18/9/26 Exercice

Chief Technology Officer

8,845 0.0533%
2/6/26 Exercice

Chief Financial Officer

5,000 0.0302%
4/3/26 Exercice

Chief Administrative Officer

1,627 0.0099%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%-23.14%-23.53%-65.35% 147M
-3.10%-4.19%+32.67%+59.47% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.46%+11.00%+44.65% 32.71B
+1.11%+15.18%+60.27%+49.33% 26.5B
+3.18%-6.72%+25.35%-8.75% 24.01B
Average -0.00%-2.47%+38.79%+132.58% 38.34B
Weighted average by Cap. -0.35%-0.59%+42.49%+153.34%

Financials

2026 *2027 *
Net sales 51.55M 46.27M 42.72M 38.74M 72.41M 4.9B 73.29M 512M 203M 2.57B 194M 189M 8.14B 31.6M 28.36M 26.18M 23.74M 44.38M 3B 44.92M 314M 125M 1.57B 119M 116M 4.99B
Net income -130M -116M -107M -97.33M -182M -12.3B -184M -1.29B -511M -6.45B -486M -476M -20.45B -141M -126M -117M -106M -198M -13.37B -200M -1.4B -555M -7.01B -528M -517M -22.22B
Net Debt - -
Projected Income Statement - Annual - Sutro Biopharma, Inc.
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
128
Date Price Change Volume
27/10/26 US$8.870 -0.17% 453,236
26/10/26 US$8.885 -4.77% 694,466
23/10/26 US$9.330 -9.33% 430,837
22/10/26 US$10.29 -4.63% 293,292
21/10/26 US$10.79 -6.50% 439,854
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Sutro Biopharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
8.870USD
Average target price
47.23USD
Spread / Average Target
+432.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sutro Biopharma, Inc.
  1. Stock Market
  2. Stocks
  3. STRO Stock